AUTHORS
Mahesh Kumar, MD, Mahmood Aldapt, M.B.B.S.2, Mehmet Uyanik, M.D.3, Hemant Murthy, MD4, Kebede Begna, M.D.5, Antoine N. Saliba, M.D.6, Naseema Gangat, MBBS7, Aref Al-Kali, M.D.8, Cecilia Arana Yi, M.D.9, Lisa Sproat, M.D.10, Mrinal M. Patnaik, MD, MBBS11, Mark R. Litzow, MD12, James Foran, FRCPC13, Talha Badar, MD14
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Mayo Clinic, Jacksonville, Florida, United States
3 MUSC, Charleston, South Carolina, United States
4 Mayo Clinic, Jacksonville, Florida, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Phoenix, Arizona, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Jacksonville, Florida, United States
14 Mayo Clinic, Jacksonville, Florida, United States
ABSTRACT
Background
Outcomes for older adults with B-cell acute lymphoblastic leukemia (B-ALL) have historically been poor, with long-term survival of approximately 20%–30%. BCR::ABL1-directed tyrosine kinase inhibitors (TKI) and earlier use of immunotherapies, including inotuzumab ozogamicin (InO) and blinatumomab (Blina), have improved outcomes, but their real-world impact remains incompletely defined. We evaluated treatment patterns, the impact of frontline immunotherapy on long-term outcomes among adults aged ≥55 years with newly diagnosed B-ALL treated at Mayo Clinic.
Methods
We retrospectively analyzed adults aged ≥55 years with B-ALL treated across three Mayo Clinic sites from August 2006 to April 2026. Frontline immunotherapy was defined as Blina or InO administered during induction or consolidation +/- chemotherapy/TKI. Because these agents were not routinely used before 2016, immunotherapy analyses were restricted to patients (pts) diagnosed from 2016 onward. Post-induction measurable residual disease (MRD) was assessed by quantitative BCR::ABL1 PCR for Ph-positive (Ph+) B-ALL and multiparameter flow cytometry (MFC) for Ph-negative (Ph-) B-ALL (sensitivity; 0.01%).
Results
A total of 106 pts were included; median age was 66 years [range 55–88]; 60% were male. Ph+ disease was present in 55 (52%) and Ph- in 51 (48%); therapy-related B-ALL accounted for 7 (7%) pts. Frontline immunotherapy was administered to 49 (46%): Blina in 43 (41%) and InO in 18 (17%), with 12 receiving both. Baseline characteristics were balanced between recipients and non-recipients of frontline Blina- or InO-based combinations; 33% underwent alloHCT.
In pts with Ph+ disease (n=55), median age was 67 years [range 55–88]; 53% were male; therapy-related B-ALL was present in 3 (5%). Frontline immunotherapy was administered to 19 (35%): Blina in 16 and 3 received Blina+InO with TKI; 16 (29%) underwent alloHCT. Median follow-up among survivors was 51.4 months [range 8.8–148.1]. Complete remission (CR) rate after induction was 83% and post-induction PCR-based MRD-negative (MRD-) was 65.5%. OS was significantly better in MRD- vs MRD-positive (MRD+), both overall (3-year OS: 77.4% vs 54.2%; p=0.023) and after censoring at alloHCT (76.9% vs 52.5%; p=0.017). Pts receiving alloHCT had 3-year OS of 81.3%.
Among pts with Ph+ diagnosed after 2016 (n=47), compared with pts who did not receive frontline immunotherapy, those who received had 3-year OS of 73.4% vs 57.1% (p=0.23), and after censoring at alloHCT was 75.6% vs 50.6% (p=0.13).
In pts with Ph- disease (n=51), median age was 65.2 years [range 55–86]; 69% were male; 16 (31%) were classified as high-risk; therapy-related B-ALL was present in 4 (8%). Frontline immunotherapy was administered to 30 (59%): Blina in 24 and InO in 15, with 9 receiving both; 19 (37%) underwent alloHCT. Median follow-up among survivors was 23.5 months [range 1.0–233.8].
CR rate after induction was 78.0% and post-induction MFC-based MRD- was 60.4%. Three-year RFS was 40.2% and 3-year OS was 65.3%. OS did not differ significantly by MRD status, either overall (3-year OS: MRD- 68.8% vs MRD+ 65.4%; p=0.376) or after censoring at alloHCT (72.7% vs 65.9%; p=0.275). Pts receiving alloHCT had 3-year OS of 78.2%.
Among Ph- pts diagnosed after 2016 (n=48), compared with pts who did not receive frontline immunotherapy, those who received had 3-year OS of 65.8% vs 53.0% (p=0.72), and after censoring at alloHCT (3-year OS: 84.8% vs 47.6%; p=0.138).
Conclusions
In this real-world cohort of adults aged ≥55 years with B-ALL, both Ph+ and Ph- subsets achieved encouraging outcomes in the modern treatment era, with 3-year OS of 77.4% and 65.3%, respectively. Post-induction MRD- was strongly associated with improved OS in Ph+ B-ALL but not in Ph- B-ALL, potentially reflecting the lower sensitivity of MFC- vs NGS-based (e.g., clonoSEQ) MRD assessment. Among patients diagnosed from 2016 onward, OS trended higher with frontline Blina- or InO-based combinations but did not reach statistical significance, likely reflecting limited power in this older, real-world cohort. These findings support earlier incorporation of immunotherapy into frontline B-ALL treatment and are consistent with emerging trial data. Interpretation is limited by small subgroup sizes, nonrandomized treatment selection, and enrichment for high-risk phenotypes; larger real-world and prospective studies are needed to define the optimal role and timing of immunotherapy in this population.
DISCLOSURES
Mahmood Aldapt, M.B.B.S.: No relevant conflicts of interest to declare.